Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (for suvorexant) Clear all
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia

NCT03034018
View directory record Official record
Conditions
Insomnia
Interventions
suvorexant, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 1, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder

NCT05711862
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
suvorexant (SUVO), Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder

NCT02849548
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
suvorexant, placebo
Drug · Other
Lead sponsor
Howard University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

NCT03657355
View directory record Official record
Conditions
Healthy Recreational Drug Users
Interventions
ACT-541468, Suvorexant, Zolpidem, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 1, 2026, 4:30 PM EDT
Not listed Phase 4 Interventional

Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia

NCT03768713
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 1, 2026, 4:30 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of Suvorexant for Sleep in Children With Autism

NCT05546554
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 1, 2026, 4:30 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

NCT06484075
View directory record Official record
Conditions
Healthy Volunteers, Alcohol Use Disorder (AUD)
Interventions
Placebo, Suvorexant
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Suvorexant for Opioid/Stimulant Co-use

NCT05546515
View directory record Official record
Conditions
Opioid Use Disorder, Stimulant Use Disorder
Interventions
Suvorexant (dual orexin receptor antagonist), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep Quality and Amyloid-Beta Kinetics

NCT03077620
View directory record Official record
Conditions
Amyloid-beta
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 1, 2026, 4:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Orexin s Role in the Neurobiology of Substance Use Disorder

NCT05630781
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Belsomra, Placebo, Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant on Post-operative Sleep Disturbance

NCT05823844
View directory record Official record
Conditions
Postoperative Insomnia, Postoperative Delirium
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 1, 2026, 4:30 PM EDT
Recruiting Phase 4 Interventional

Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

NCT03642028
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Stress Disorders, Posttraumatic
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Long Beach, California • San Francisco, California • Salisbury, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 1, 2026, 4:30 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Suvorexant and Alcohol

NCT06326684
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Alcohol, Placebo, Suvorexant
Drug
Lead sponsor
William Stoops
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 4 Interventional Results available

Suvorexant and Sleep/Delirium in ICU Patients

NCT04092894
View directory record Official record
Conditions
Insomnia, Sleep Fragmentation, Sleep Initiation and Maintenance Disorders, Postoperative Delirium
Interventions
Suvorexant 20 mg, Placebo oral tablet
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 4 Interventional Results available

Suvorexant and Trauma Related Insomnia

NCT02704754
View directory record Official record
Conditions
Insomnia, Posttraumatic Stress Disorder
Interventions
suvorexant, placebo
Drug · Other
Lead sponsor
Howard University
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant

NCT05733286
View directory record Official record
Conditions
Delirium in Old Age
Interventions
Suvorexant 20 mg, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Suvorexant to Reduce Symptoms of Nicotine Use

NCT04234997
View directory record Official record
Conditions
Smoking Cessation
Interventions
Suvorexant 20 mg, Suvorexant 0mg
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Medication Development in Alcoholism: Suvorexant Versus Placebo

NCT04229095
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Suvorexant 20 mg, Placebo oral tablet
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes

NCT05908526
View directory record Official record
Conditions
Insomnia
Interventions
Baseline surveys, Cognitive testing and EMAs, Actiwatch, suvorexant (or placebo), Placebo
Behavioral · Device · Drug + 1 more
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 1, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional

Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder

NCT04262193
View directory record Official record
Conditions
Opioid-use Disorder, Sleep
Interventions
Suvorexant, Suvorexant Placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use

NCT02785406
View directory record Official record
Conditions
Cocaine Use Disorder, Anxiety
Interventions
suvorexant, Placebo (for suvorexant)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
19 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

NCT02729714
View directory record Official record
Conditions
Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Burdick, Daniel, M.D.
Individual
Eligibility
30 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 1, 2026, 4:30 PM EDT
Completed Phase 2 Interventional

Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl

NCT05145764
View directory record Official record
Conditions
Suvorexant, Placebo, Opioid Use Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 1, 2026, 4:30 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Measuring Acute Drug Demand in Humans

NCT05829655
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence
Interventions
Drug A (Blinded Drug), Drug B (Blinded Drug), Drug C (Blinded Drug), Drug D (Blinded Drug), Suvorexant (20mg/day), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 1, 2026, 4:30 PM EDT